(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 14.48% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 13.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.
10x Genomics's revenue in 2024 is $618,727,000.On average, 6 Wall Street analysts forecast TXG's revenue for 2024 to be $80,746,416,049, with the lowest TXG revenue forecast at $79,917,255,235, and the highest TXG revenue forecast at $81,688,665,912. On average, 6 Wall Street analysts forecast TXG's revenue for 2025 to be $94,914,483,964, with the lowest TXG revenue forecast at $89,589,407,779, and the highest TXG revenue forecast at $102,809,744,171.
In 2026, TXG is forecast to generate $115,058,158,229 in revenue, with the lowest revenue forecast at $105,690,595,372 and the highest revenue forecast at $123,890,305,804.